Georgia Erbez - 12 Jun 2025 Form 4 Insider Report for Coherus Oncology, Inc. (CHRS)

Reporting relationship: Director
Issuer ticker: CHRS
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 18:48:16 UTC
Prior SEC filing: 07 Feb 2025
Next SEC filing: 15 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Bryan McMichael, as Attorney-in-Fact for Georgia Erbez

Key filing fact

Georgia Erbez filed Form 4 for Coherus Oncology, Inc. (CHRS) on 13 Jun 2025.

Key facts

This page summarizes Georgia Erbez's Form 4 filing for Coherus Oncology, Inc. (CHRS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 18:48.

Change

Previous filing in this sequence was filed on 07 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001557930 Primary reporting owner

Erbez Georgia

Relationship: Director
Address: C/O COHERUS ONCOLOGY, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY
Signature: /s/ Bryan McMichael, as Attorney-in-Fact for Georgia Erbez
Signature date: 13 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +112,000
Change %
Price: $0.000000
Shares after: 112,000
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 112,000
Exercise price: $0.7904
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.